Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.

Abstract

OBJECTIVES:

This study evaluated the clinical significance of urinary CA19-9 levels in bladder cancer patients classified according to various combinations of Lewis (Le) and Secretor (Se) genotypes.

METHODS:

Urinary CA19-9 and DU-PAN-2 levels were measured as units per mg creatinine (U/mg Cr) in 121 patients with bladder cancer and in 31 patients with other urologic diseases. Genotyping was carried out using polymerase chain reaction-based methods.

RESULTS:

Urinary CA19-9-values in patients with both Le and Se alleles (Le/Le, Se/Se; Le/Le, Se/se; Le/le, Se/Se; Le/le, Se/se) were significantly higher (P < 0.0001) in bladder cancer cases compared to the other urologic diseases. The cut-off value determined using receiver operating characteristics analyses was 37.6 U/mg Cr. Approximately 70% (57/87) of bladder cancer patients with both Le and Se alleles demonstrated urinary CA19-9 levels over the cut-off value. In contrast, only 16% (4/24) of patients with other urologic diseases were over the cut-off value.

CONCLUSIONS:

The urinary CA19-9 level can be a new effective diagnostic tool in bladder cancer patients with both Le and Se alleles.

• Authors: Keiji Nagao, Yukio Itoh, Kazuhiko Fujita, Makoto Fujime
• Journal: International journal of urology : official journal of the Japanese Urological Association (Int J Urol) Vol. 14 Issue 9 Pg. 795-9 (Sep 2007) ISSN: 0919-8172 [Print] Australia
• PMID: 17760744 (Publication Type: Evaluation Study, Journal Article)

Chemical References

• Antigens, Neoplasm
• CA-19-9 Antigen
• DU-PAN-2 antigen, human

Topics

• Adult
• Aged
• Aged, 80 and over
• Alleles
• Antigens, Neoplasm (urine)
• CA-19-9 Antigen (urine)
• Case-Control Studies
• Female
• Genotype
• Humans
• Male
• Middle Aged
• Urinary Bladder Neoplasms (diagnosis, genetics, urine)